Global News and Digital Insights
for the Healthcare Industry

Reprocell USA to support Lantern Pharma’s Phase 2 clinical trial

Reprocell USA, a contract research organisation (CRO), has been awarded a contract to support Lantern Pharma’s Phase 2 clinical trial for its investigational new drug LP-300 in combination with carboplatin and pemetrexed. The trial aims to determine clinical advantages for the drug in combination with other treatments in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors. Reprocell will produce specimen collection kits, process patient samples and store biomaterial from patients in this study. The company will also provide cell-free DNA from plasma, genomic DNA and/or RNA from the buffy coat fraction, and archive pathology FFPEs and associated H&E-stained slides from selected patients. Reprocell will retain all biomaterials and pathology materials on-site until required by Lantern Pharma.

Read more from Contractpharma
Facebook
Twitter
LinkedIn